Triple therapy for chronic obstructive pulmonary disease (COPD) generally refers to a triple combination of inhaled long-acting β2 agonists, inhaled M-blockers, and inhaled glucocorticosteroids, which has the effect of treating COPD. Although this type of medication has a better therapeutic effect on the treatment of COPD, curing COPD is not a reliable option.
Inhalation of triple compound preparation commonly used budesonide, flutimafir, repeated acute exacerbation of chronic obstructive pulmonary disease or accompanied by obvious eosinophil elevation and other related conditions, it may be necessary to consider the use of such drugs for treatment, can improve the condition, but can not cure chronic obstructive pulmonary disease.
COPD is a disease characterized by persistent airflow limitation, which is not completely reversible and progressively develops. With standardized treatment, symptoms can be improved and disease progression can be slowed down, but it is not a complete cure, and the effects of the above triple combination of drugs should not be over-exaggerated.
Patients with chronic obstructive pulmonary disease need standardized treatment under the guidance of a physician. These drugs should be used under the supervision of a physician.